Company intelligence / Profile preview

MDD US Operations

Louisville, Kentucky, United Statesopenpaymentsdata.cms.gov ↗

Ownership: Private
Employees: ~150
Development stage: Other

Overview

MDD US Operations has several approved drugs, including apomorphine hydrochloride for Parkinson disease, safinamide mesylate for Parkinson disease, eflornithine hydrochloride for high-risk neuroblastoma, botulinum toxin type B for cervical dystonia, and lofexidine hydrochloride for substance withdrawal syndrome. The company’s products are commercialized in the U.S. and Europe.

Therapeutic areas: PsychiatryNeurologyOncology
Modalities: Small moleculeToxin
Industry: Biotech

Beyond the preview

Go deeper on MDD US Operations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDD US Operations.

Explore the full profile